All In Biotech

Drug Trial Radar · NCT07489495

A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)

A Phase 3, Randomized, Double-blind, Study of Belzutifan + Zanzalintinib Versus Belzutifan + Placebo in Participants With Advanced RCC Who Have Progressed on or After Both PD-1/L1 and VEGF-TKI Therapies in Sequence or in Combination (LITESPARK-034)

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 758 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

758

Planned (sponsor's estimate)

Start

Apr 9, 2026

Primary completion

Nov 27, 2030

Study completion Nov 27, 2030

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
Collaborators
Exelixis
First posted
Mar 24, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for new ways to treat advanced renal cell carcinoma (RCC). A standard (usual) treatment for certain people with RCC is belzutifan (a study medicine), which is a targeted therapy. Targeted therapy is a treatment that works to control how specific types of cancer cells grow and spread. Researchers want to learn if adding another targeted therapy called zanzalintinib (another study medicine) can treat more people with advanced RCC than belzutifan alone. The goal of this study is to learn if people who receive belzutifan and zanzalintinib live longer overall and without the cancer getting worse compared to people who receive belzutifan and placebo.

Conditions

  • Carcinoma, Renal Cell

Interventions

  • BelzutifanDrug

    Tablet for oral administration.

  • ZanzalintinibDrug

    Tablet for oral administration.

  • PlaceboDrug

    Zanzalintinib-matching placebo tablet for oral administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS)Time frame: Up to approximately 30 months
  2. Overall Survival (OS)Time frame: Up to approximately 50 months

Locations

111 sites in 19 countries. Site status is shown where the registry gives one.

  • City of Hope Comprehensive Cancer Center ( Site 0129)

    Duarte, California · Recruiting

  • City of Hope Lennar Foundation Cancer Center ( Site 0142)

    Irvine, California · Recruiting

  • Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital ( Site 0102)

    Marietta, Georgia · Recruiting

  • University of Louisville, James Graham Brown Cancer Center ( Site 0133)

    Louisville, Kentucky · Recruiting

  • Norton Women's and Children's Hospital-Norton Cancer Institute - St. Matthews ( Site 0104)

    Louisville, Kentucky · Recruiting

  • Beth Israel Deaconess Medical Center ( Site 0139)

    Boston, Massachusetts · Recruiting

  • Dana Farber Cancer Institute ( Site 0135)

    Boston, Massachusetts · Recruiting

  • The Cancer and Hematology Centers ( Site 0123)

    Grand Rapids, Michigan · Recruiting

  • Washington University School of Medicine ( Site 0114)

    St Louis, Missouri · Recruiting

  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 0108)

    Hackensack, New Jersey · Recruiting

  • Atlantic Health System Morristown Medical Center ( Site 0109)

    Morristown, New Jersey · Recruiting

  • Memorial Sloan Kettering Cancer Center ( Site 0126)

    New York, New York · Recruiting

  • The West Clinic, P.C. ( Site 0115)

    Germantown, Tennessee · Recruiting

  • UT Southwestern Medical Center ( Site 0119)

    Dallas, Texas · Recruiting

  • Instituto Alexander Fleming ( Site 0252)

    CABA, Argentina · Recruiting

  • Centro Oncológico Riojano Integral ( Site 0256)

    La Rioja, Argentina · Recruiting

  • COE (Centro Oncológico de Excelencia) ( Site 0259)

    San Juan, Argentina · Recruiting

  • Centro Oncologico Korben ( Site 0254)

    CABA, Buenos Aires, Argentina · Recruiting

  • Hospital Italiano de Buenos Aires ( Site 0253)

    Ciudad de Buenos Aires, Buenos Aires, Argentina · Recruiting

  • Instituto de Investigaciones Clinicas Mar del Plata ( Site 0250)

    Mar del Plata, Buenos Aires, Argentina · Recruiting

  • Centro Privado de RMI Río Cuarto S.A. II ( Site 0255)

    Río Cuarto, Córdoba Province, Argentina · Recruiting

  • Sanatorio Parque ( Site 0251)

    Rosario, Santa Fe Province, Argentina · Recruiting

  • Instituto de Oncología de Rosario ( Site 0257)

    Rosario, Santa Fe Province, Argentina · Recruiting

  • Macquarie University ( Site 2700)

    Macquarie University, New South Wales, Australia · Suspended

  • Princess Alexandra Hospital ( Site 2703)

    Woolloongabba, Queensland, Australia · Suspended

  • Peter MacCallum Cancer Centre ( Site 2702)

    Melbourne, Victoria, Australia · Suspended

  • Fiona Stanley Hospital ( Site 2704)

    Murdoch, Western Australia, Australia · Suspended

  • CEDOES ( Site 0303)

    Vitória, Espírito Santo, Brazil · Recruiting

  • Instituto do Câncer e Transplante de Curitiba ( Site 0300)

    Curitiba, Paraná, Brazil · Recruiting

  • Liga Norte Riograndense Contra o Câncer ( Site 0307)

    Natal, Rio Grande do Norte, Brazil · Recruiting

  • Hope - Humanizacao Em Oncologia, Pesquisa E Ensino ( Site 0306)

    Ribeirão Preto, São Paulo, Brazil · Recruiting

  • Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 0302)

    São José do Rio Preto, São Paulo, Brazil · Recruiting

  • The Ottawa Hospital Cancer Centre ( Site 0003)

    Ottawa, Ontario, Canada · Recruiting

  • Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0001)

    Québec, Quebec, Canada · Recruiting

  • IC La Serena Research ( Site 0405)

    La Serena, Coquimbo Region, Chile · Recruiting

  • Clínica Puerto Montt ( Site 0404)

    Port Montt, Los Lagos Region, Chile · Recruiting

  • Fundacion Arturo Lopez Perez ( Site 0401)

    Santiago, Region M. de Santiago, Chile · Recruiting

  • Bradfordhill ( Site 0400)

    Santiago, Region M. de Santiago, Chile · Recruiting

  • ONCOCENTRO APYS ( Site 0403)

    Viña del Mar, Valparaiso, Chile · Recruiting

  • Fakultni nemocnice Hradec Kralove ( Site 0902)

    Hradec Králové, Czechia · Recruiting

Showing 40 of 111 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.